Fiscal Year 2011 Annual Review of Amitiza® (Lubiprostone)

Oklahoma Health Care Authority
April 2012

Current Prior Authorization of Amitiza®

1. Chronic Idiopathic Constipation in males and females 18 years of age and older who meet the following criteria, or IBS-Constipation predominant in females 18 years of age or older:
   a. Have documentation that constipation-causing therapies for other disease states have been discontinued (excluding opioid pain medications for cancer patients).
   b. Documented and updated Colon Screening. (>50 years of age)
2. Hydration and treatment attempts with a minimum of three alternate products must be documented.
3. Initial approval for 12 weeks of therapy. An additional year approval may be granted if physician documents member is responding well to treatment.
4. Quantity limit of 100 units for a 50 day supply applies.

Utilization of Amitiza®

Comparison of Fiscal Year Utilization

<table>
<thead>
<tr>
<th>Fiscal Year</th>
<th>Members</th>
<th>Claims</th>
<th>Paid</th>
<th>Paid/Claim</th>
<th>Perdiem</th>
<th>Units</th>
<th>Days</th>
</tr>
</thead>
<tbody>
<tr>
<td>2010</td>
<td>61</td>
<td>197</td>
<td>$39,608.13</td>
<td>$201.06</td>
<td>$6.76</td>
<td>11,152</td>
<td>5,862</td>
</tr>
<tr>
<td>2011</td>
<td>68</td>
<td>238</td>
<td>$50,945.97</td>
<td>$214.06</td>
<td>$7.17</td>
<td>13,528</td>
<td>7,109</td>
</tr>
<tr>
<td>% Change</td>
<td>11.50%</td>
<td>20.80%</td>
<td>28.60%</td>
<td>6.50%</td>
<td>6.10%</td>
<td>21.30%</td>
<td>21.30%</td>
</tr>
<tr>
<td>Change</td>
<td>7</td>
<td>41</td>
<td>$11,337.84</td>
<td>$13.00</td>
<td>$0.41</td>
<td>2,376</td>
<td>1,247</td>
</tr>
</tbody>
</table>

Demographics of Members Utilizing Amitiza®: FY 2011
### Prescribers of Amitiza®: FY 2011

![Bar chart showing the number of claims by prescriber type for FY 2011](chart)

### Utilization Details: FY 2011

<table>
<thead>
<tr>
<th>Medication</th>
<th>Claims</th>
<th>Units</th>
<th>Days</th>
<th>Members</th>
<th>Paid</th>
<th>Units/Day</th>
<th>Claims/Member</th>
<th>Per-diem</th>
</tr>
</thead>
<tbody>
<tr>
<td>AMITIZA CAP 24MCG</td>
<td>177</td>
<td>10,180</td>
<td>5,420</td>
<td>47</td>
<td>$38,152.71</td>
<td>1.88</td>
<td>3.77</td>
<td>$7.04</td>
</tr>
<tr>
<td>AMITIZA CAP 8MCG</td>
<td>61</td>
<td>3,348</td>
<td>1,689</td>
<td>22</td>
<td>$12,793.26</td>
<td>1.98</td>
<td>2.77</td>
<td>$7.57</td>
</tr>
<tr>
<td><strong>Totals</strong></td>
<td><strong>238</strong></td>
<td><strong>13,528</strong></td>
<td><strong>7,109</strong></td>
<td><strong>68</strong></td>
<td><strong>$50,945.97</strong></td>
<td><strong>1.9</strong></td>
<td><strong>3.5</strong></td>
<td><strong>$7.17</strong></td>
</tr>
</tbody>
</table>

*Total Number of Unduplicated Members

### Prior Authorization of Amitiza® Products

There were a total of 246 petitions submitted for this PBPA category during fiscal year 2011. The following shows the status of the submitted petitions.

![Pie chart showing the status of petitions for FY 2011](chart)

**Status of Petitions for Amitiza®: FY 2011**

- **Approved**: 87, 35%
- **Incompleted**: 145, 59%
- **Denied**: 14, 6%

### Conclusion and Recommendations

The College of Pharmacy recommends no changes to this category at this time.